Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?-Reference-Cited by-同舟云学术

Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?

Published:2023-04 Issue: Volume:46 Page:101173
ISSN:2352-5789
Container-title:Gynecologic Oncology Reports
language:en
Short-container-title:Gynecologic Oncology Reports

Author:

Levine Monica D.,O'Malley David M.,Haight Paulina J.,Senter Leigha,Wagner Vincent,Bixel Kristin L.,Cohn David E.,Copeland Larry J.,Cosgrove Casey M.,McLaughlin Eric M.,Backes Floor J.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference22 articles.

1. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study;Bell;Gynecol. Oncol.,2006

2. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study;Chan;Gynecol. Oncol.,2010

3. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study;Chan;Gynecol. Oncol.,2010

4. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: an NRG/GOG ancillary study;Chan;Gynecol. Oncol.,2022

5. Chan, Mar. 2010. Oncology Group study. Gynecol. Oncol. 116(3), 37–17. this looks duplicated.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer;Critical Reviews in Oncology/Hematology;2024-10

2. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status;Gynecologic Oncology;2024-08